![]() 7, 8 The virus is believed to target the upper respiratory tract, in particular, with a natural history characterized by high‐grade fever, cough, and shortness of breath. Transmitted primarily through respiratory droplets released into the air upon coughing or sneezing, SARS‐CoV‐2 can frequently lead to pneumonia in individuals exposed to a sufficient amount of viral particles. 1, 2, 3 The substantial disease burden associated with COVID‐19 necessitated the development of novel techniques for detection of SARS‐CoV‐2 and repurposing of drugs with potential therapeutic value, including lopinavir, ritonavir, chloroquine/hydroxychloroquine, oseltamivir, darunavir, zanamivir, peramivir, and remdesivir. The causative virus, Severe Acute Respiratory Coronavirus 2 (SARS‐CoV‐2), had infected 109,594,835 people as of May 7, 2020, resulting in 2,424,060 deaths. Soon after, the rapid spread of COVID‐19 in the world prompted nations to recognized it as a global threat. In December 2019, the first cases of Coronavirus Disease 2019 (COVID‐19) were reported in Wuhan, China. ![]() In this review, we seek to investigate the coinfection of SARS‐CoV‐2 with other respiratory and nonrespiratory viruses to provide novel insights into the development of highly sensitive diagnostics and effective treatment modalities. Given the resulting changes in blood markers, such as coagulation factors and white blood cell count following virus infection, these markers can be of diagnostic value in the detection of mixed infection in individuals already diagnosed with a certain viral illness. Due to the similarity in clinical symptoms of most viral respiratory tract infections, and their coincidence with COVID‐19, caused by SARS‐CoV‐2, it is recommended to develop a comprehensive diagnostic panel for detection of respiratory and nonrespiratory viruses through the evaluation of patient samples. These genetically similar viruses can interfere with the replication process of each other and even compete for the metabolites required for the maintenance of the replication cycle. With patient satisfaction ratings above 90% and many clinics accredited by CARF and Accreditation Canada, Lifemark’s patients and customers always receive the highest level of care for their rehabilitation needs.The most consequential challenge raised by coinfection is perhaps the inappropriate generation of recombinant viruses through the exchange of genetic material among different strains. ![]() Lifemark Health Group was honoured to receive the Employee Recommended Workplace award in both 20, and the Canada’s Most Admired Corporate Cultures™ award in 2019. The company aims to be the most innovative healthcare provider in community rehabilitation, workplace health and wellness and medical assessment services. As a national healthcare company, LHG employs over 5,000 highly-trained clinicians, medical experts and team members in over 300 locations coast-to-coast. With over 20 years of service excellence, LHG is one of the largest, most trusted, and most comprehensive providers in Canada. Lifemark Health Group (LHG) is a market leader in customized healthcare solutions. We will continue to enhance the program as we learn more about the virus and the lingering issues that arise for people long after the virus is over.” The program will “address the post-acute and long-term needs as more and more people are affected by this pandemic” said Gilles Chabot Chief Operating Officer, Clinic Operations of Lifemark Health Group.“The program was developed in collaboration with top healthcare professionals and rooted in the latest research. Whether you need physical exercise, manual therapy, vestibular therapy or cognitive behavioral therapy, we’ll design a plan that gives you the care you need to help you get back on your feet. The Lifemark Health Group multi-disciplinary approach to post COVID-19 rehabilitation involves professionals from over 15 disciplines, from physiotherapists to registered nurses and dieticians. ![]() Our professionals will examine your medical history and work closely with doctors and other specialists (with your consent), to ensure that your treatment plan is right for you. The program is designed to tailor to your unique healthcare needs. If you’ve been dealing with pandemic related anxiety, struggling to return to work, or if you’ve recovered from the virus but continue to experience debilitating symptoms – we’re here to help. That’s why we’re excited to announce the launch of our Post COVID-19 Rehabilitation and Recovery Program. Toronto, ON – October 5, As the COVID-19 pandemic continues to impact Canadians from coast to coast, Lifemark Health Group remains committed to developing new ways to support those that have been affected by the virus.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |